Cite

HARVARD Citation

    Preusse, C. et al. (2021). NanoString technology distinguishes anti‐TIF‐1γ+ from anti‐Mi‐2+ dermatomyositis patients. Brain pathology. p. n/a. [Online]. 
  
Back to record